NASDAQ:CFRX - ContraFect Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.41 -0.03 (-1.23 %)
(As of 07/22/2018 06:18 AM ET)
Previous Close$2.41
Today's Range$2.3701 - $2.47
52-Week Range$0.80 - $2.93
Volume73,226 shs
Average Volume154,162 shs
Market Capitalization$177.52 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.45
ContraFect logoContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.

Receive CFRX News and Ratings via Email

Sign-up to receive the latest news and ratings for CFRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CFRX
CUSIPN/A
Phone914-207-2300

Debt

Debt-to-Equity RatioN/A
Current Ratio10.63
Quick Ratio10.63

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.42 per share
Price / Book5.74

Profitability

EPS (Most Recent Fiscal Year)($0.37)
Net Income$-15,510,000.00
Net MarginsN/A
Return on Equity-87.85%
Return on Assets-45.63%

Miscellaneous

Employees23
Outstanding Shares73,660,000
Market Cap$177.52

ContraFect (NASDAQ:CFRX) Frequently Asked Questions

What is ContraFect's stock symbol?

ContraFect trades on the NASDAQ under the ticker symbol "CFRX."

How were ContraFect's earnings last quarter?

ContraFect Corp (NASDAQ:CFRX) posted its quarterly earnings data on Thursday, May, 10th. The biotechnology company reported ($0.09) EPS for the quarter, meeting analysts' consensus estimates of ($0.09). View ContraFect's Earnings History.

When is ContraFect's next earnings date?

ContraFect is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for ContraFect.

What price target have analysts set for CFRX?

3 analysts have issued 12 month target prices for ContraFect's shares. Their predictions range from $2.80 to $2.80. On average, they anticipate ContraFect's stock price to reach $2.80 in the next twelve months. This suggests a possible upside of 16.2% from the stock's current price. View Analyst Ratings for ContraFect.

What is the consensus analysts' recommendation for ContraFect?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ContraFect in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of ContraFect's key competitors?

Who are ContraFect's key executives?

ContraFect's management team includes the folowing people:
  • Dr. Steven C. Gilman, Exec. Chairman, CEO & Pres (Age 65)
  • Mr. Michael Messinger, Sr. VP of Fin. & Chief Accounting Officer (Age 43)
  • Ms. Nancy Dong, VP of Fin. & Admin. (Age 53)
  • Ms. Natalie Bogdanos J.D., Gen. Counsel & Corp. Sec. (Age 49)
  • Dr. Cara Cassino, Chief Medical Officer and Exec. VP of R&D (Age 56)

Has ContraFect been receiving favorable news coverage?

Media coverage about CFRX stock has trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. ContraFect earned a media sentiment score of 0.08 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 46.46 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

How do I buy shares of ContraFect?

Shares of CFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ContraFect's stock price today?

One share of CFRX stock can currently be purchased for approximately $2.41.

How big of a company is ContraFect?

ContraFect has a market capitalization of $177.52 million. The biotechnology company earns $-15,510,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. ContraFect employs 23 workers across the globe.

How can I contact ContraFect?

ContraFect's mailing address is 28 WELLS AVENUE 3RD FLOOR, YONKERS NY, 10701. The biotechnology company can be reached via phone at 914-207-2300 or via email at [email protected]


MarketBeat Community Rating for ContraFect (NASDAQ CFRX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  133 (Vote Outperform)
Underperform Votes:  97 (Vote Underperform)
Total Votes:  230
MarketBeat's community ratings are surveys of what our community members think about ContraFect and other stocks. Vote "Outperform" if you believe CFRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CFRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/22/2018 by MarketBeat.com Staff

Featured Article: Earnings Per Share

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.